Redfund Capital Corp. (CSE:LOAN, Frankfurt:O3X4, OTCQB:PNNRF) (Redfund or the “Company”) is pleased to announce CannaForum BV “CANNA” our newest portfolio client, has been notified it remains in the last 40 cannabis applications and that over 100 other submissions have been rejected to date by the Dutch government in their Closed Cannabis Supply Chain Experiment.

Redfund previously announced on July 29 that the Company had signed a letter of intent with CannaForum BV a company registered in the Netherlands, that had submitted an application for a cannabis cultivation license to the Dutch government in a new experiment program for the legal cultivation of cannabis in the Netherlands. Redfund and CannaForum have begun discussing a definitive agreement and terms will be disclosed when appropriate. 10 Cannabis producers will be awarded licenses in early 2021 and will be the only companies allowed to legally operate from 2021 to at least 2025 in the Netherlands. The Dutch experiment includes 79 retailers / `Coffeeshops’ within 10 selected cities. All retailers in the experiment are required to purchase all their products from the 10 selected producers. According to the application submitted to the Netherlands government, a minimum of 65.000 kg is required to be produced by 10 producers on an annual basis to supply all 79 retailers. For each producer: 6.500 kg at current Dutch wholesale prices translates to approx. 12-20m revenues annually.

Keep reading... Show less

FSD Pharma Inc. (formerly, Century Financial Capital Group Inc., the “Corporation”) is pleased to announce that it has completed its previously announced business combination with FV Pharma Inc. (“FV Pharma”). On March 9, 2018 the Corporation and FV Pharma entered into an arm’s length definitive business combination agreement (the “Business Combination Agreement”) with 2620756 Ontario Inc. (“SubCo”), a wholly-owned subsidiary of the Corporation, incorporated for the purpose of this transaction. Pursuant to the Business Combination Agreement, the Corporation changed its name to FSD Pharma Inc. and completed a business combination with FV Pharma by way of a three-cornered amalgamation pursuant to which FV Pharma amalgamated with SubCo (the “Transaction”). The resulting amalgamated corporation carried on in the name of FV Pharma as a wholly-owned subsidiary of the Corporation. Following the completion of the Transaction, FSD Pharma Inc. will carry on the medical cannabis business of FV Pharma. For the purposes of this press release, the term “Resulting Issuer” means the Corporation following completion of the Transaction.

On March 15, 2018, the Corporation held an annual and special meeting of the shareholders of the Corporation (the “Shareholders”), where the Shareholders approved a share re-designation, a name change, and other matters relating to the Transaction.

Keep reading... Show less

Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to announce that Naturally Splendid Director and President of the Canadian Hemp Trade Alliance (CHTA), Mr. Russ Crawford, was a key speaker at the recent Senate hearing on May 23rd, 2018, to review hemp and its inclusion under Bill C-45 the Cannabis Act.

Representing the CHTA, Mr. Crawford acknowledged the fine work of the Marijuana Task Force in developing Proposed Regulations for the new Act which include important changes and reduced regulation for the production, processing and commercial sale of industrial hemp. The CHTA spoke in favour of Senate support for Bill C-45 which will provide a less regulated commercial environment for the hemp industry in Canada.

Keep reading... Show less

INDIVA Limited (the “Company” or “INDIVA”) (TSXV:NDVA) is pleased to announce its new brand identity, website and product packaging. “The new clean aesthetic and pallet are both mature and contemporary, but still classic enough to be lasting. This is the natural evolution of INDIVA’s original positioning, which celebrated the grassroots activism of our grower, Pete Young,” said Tomasz Borowicz, Chief Brand Officer, INDIVA, and creator of the new brand and logo.

The original INDIVA brand identity was launched in 2015 and, since then, the cannabis industry has undergone significant changes and so has INDIVA. INDIVA is now a fully financed licensed producer listed on the TSX Venture Exchange with international partnerships and close to 30 employees.

Keep reading... Show less

Nutritional High International Inc. (the “Company” or “Nutritional High”) (CSE:EAT) (OTCQB:SPLIF) (FRANKFURT:2NU) is pleased to comment on the proposed extension of emergency cannabis regulations currently in effect by California’s 3 licensing authorities: The Bureau of Cannabis Control, the Department of Public Health, and the Department of Food and Agriculture (collectively referred to as the “Licensing Authorities”). The proposed extension was previously announced to the public on May 18th, 2018. Under the terms of the extension, the Licensing Authorities are proposing to extend the regulations for an additional 180 days and implement amendments to the current regulatory structure with the intent of providing greater clarity to licensees and address issues that have been identified by licensees since the commencement of the emergency regulations.

Key parts of the proposed changes include:

Keep reading... Show less

CROPS Inc. (TSXV:COPS) announces that it proposes to complete, subject to stock exchange approval, a non-brokered private placement of convertible debentures to raise gross proceeds of up to $6.0 million. The debentures will have a term of three years, and will be convertible, at the election of the holder, into common shares of the Company at the rate of $0.08 per share (for an aggregate maximum of 75 million shares) if converted in the first year, or at the rate of $0.10 per share (for an aggregate maximum of 60 million shares) if converted in the second or third years. The Company will also issue warrants entitling the debenture holders to purchase up to a total of 37.5 million common shares exercisable at a price of $0.08 per share for up to three years.

The debentures will bear interest which is paid quarterly in cash at the annual rate of 8%. The Company may, however, subject to stock exchange approval at the time, elect to pay the interest in common shares of the Company, in which case the annual interest rate for the applicable payment will be 10% rather than 8%.

Keep reading... Show less